Wong WP, Feng J, Pwee KH, Lim J. A systematic review of economic evaluations of cardiac rehabilitation. BMC Health Serv Res. 2012;12:1–8.
Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979;301:61.
Faxon DP. Coronary interventions and their impact on post myocardial infarction survival. Clin Cardiol. 2005;28(11 Suppl 1):I38–44.
Gillies MA, Shah AS, Mullenheim J, Tricklebank S, Owen T, Antonelli J, Strachan F, Mills NL, Pearse RM. Perioperative myocardial injury in patients receiving cardiac output-guided haemodynamic therapy: a substudy of the OPTIMISE trial. Br J Anaesth. 2015;115:227–33.
Verma S, Pw F, Rd W, J B, Maitland A, Li R-K, Dhillon B, Yau TM. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation. 2002;105:2332–6.
Zeymer U, Suryapranata H, Jp OG, Davies J, Rasmanis G, Linssen G, Tebbe U, Schroder R, Tiemann R, Machnig T. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol. 2001;38:1644.
European Study of Prevention of Infarct with Molsidomine (ESPRIM) Group. The ESPRIM trial: short-term treatment of acute myocardial infarction with molsidomine. The Lancet. 1994;344(8915):91–97
Wall TC, Rm C, J B, Jd T, M T, M S, G G, Md C, M S, Leimberger JD. Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the thrombolysis and angioplasty in myocardial infarction 9 trial. TAMI 9 research group. Circulation. 1994;90:114–20.
Matsuo H, Watanabe S, Segawa T, Yasuda S, Hirose T, Iwama M, Tanaka S, Yamaki T, Matsuno Y, Tomita M. Evidence of pharmacologic preconditioning during PTCA by intravenous pretreatment with ATP-sensitive K+ channel opener nicorandil. Eur Heart J. 2003;24:1296–303.
Ishida H, Higashijima N, Hirota Y, Genka C, Nakazawa H, Nakaya H, Sato T. Nicorandil attenuates the mitochondrial Ca2+ overload with accompanying depolarization of the mitochondrial membrane in the heart. Naunyn Schmiedeberg's Arch Pharmacol. 2004;369:192–7.
Sugimoto KIH, Iwakura K. Intravenous Nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction. Circ J. 2003;67(4):295–300.
Mizumura T, Nithipatikom K, Gross GJ. Infarct size-reducing effect of nicorandil is mediated by the KATP channel but not by its nitrate-like properties in dogs. Cardiovasc Res. 1996;32:274–85.
Miyoshi T, Ejiri K, Kohno K, Nakahama M, Doi M, Munemasa M, Murakami M, Takaishi A, Kawai Y, Sato T. Effect of remote ischemia or nicorandil on myocardial injury following percutaneous coronary intervention in patients with stable coronary artery disease: A randomized controlled trial. Int J Cardiol. 2017;236:36–42.
Yamada K, Isobe S, Ishii H, Yokouchi K, Iwata H, Sawada K, Murohara T. Impacts of nicorandil on infarct myocardium in comparison with nitrate: assessed by cardiac magnetic resonance imaging. Heart Vessel. 2016;31:1430–7.
Ishii H, Ichimiya S, Kanashiro M, Amano T, Imai K, Murohara T, Matsubara T. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation. 2005;112:1284.
Isono T, Kamihata H, Sutani Y, Motohiro M, Yamamoto S, Kyoui S, Iharada Y, Kurimoto K, Hara K, Takahashi H. Nicorandil suppressed myocardial injury after percutaneous coronary intervention. Int J Cardiol. 2008;123:123–8.
Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, Hori M, Higashino Y, Fujii K, Minamino T. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction - its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Am Coll Cardiol. 1999;33:654–60.
Kawai Y, Hisamatsu K, Matsubara H, Dan K, Akagi S, Miyaji K, Munemasa M, Fujimoto Y, Kusano KF, Ohe T. Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon. Eur Heart J. 2009;30:765–72.
Kim SJ, Kim W, Woo JS, Ha SJ, Kang WY, Hwang SH, Kang DG, Lee SU, Cho SK, Im JS. Effect of myocardial protection of intracoronary adenosine and nicorandil injection in patients undergoing non-urgent percutaneous coronary intervention: a randomized controlled trial. Int J Cardiol. 2012;158:88.
Ono H, Osanai T, Ishizaka H, Hanada H, Kamada T, Onodera H, Fujita N, Sasaki S, Matsunaga T, Okumura K. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am Heart J. 2004;148:611.
Akagi T, Sarazawa K, Inai Y, Kitagawa M, Takahashi N, Hamanaka I, Yamazaki T, Takebe M, Hama N, Hiraoka Y. Continuous administration of nicorandil decreases QT dispersion during the chronic phase of acute myocardial infarction. Int Heart J. 2006;47:351.
Chen C, Xianghua FU, Wei LI, Jia X, Bai S, Geng W, Xing K. Intracoronary administration of anisodamine and nicorandil in individuals undergoing primary percutaneous coronary intervention for acute inferior myocardial infarction: A randomized factorial trial. Exp Ther Med. 2015;10:1059.
Fujiwara T, Matsunaga T, Kameda K, Abe N, Ono H, Higuma T, Yokoyama J, Hanada H, Osanai T, Okumura K. Nicorandil suppresses the increases in plasma level of matrix metalloproteinase activity and attenuates left ventricular remodeling in patients with acute myocardial infarction. Heart Vessel. 2007;22:303–9.
Kim JH, Jeong MHYun KH, Kim KH, Kang DK, Hong SN, Lim SY, Lee SH, Lee YS, Hong YJ, Park HW. Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina. Circ J. 2005;69:306–10.
Hwang J, Han CL, Kim BW, Mi JY, Park JS, Park JH, Lee HW, Oh J, Choi JH, Cha KS. The effect on periprocedural myocardial infarction of intra-coronary nicorandil prior to percutaneous coronary intervention in stable and unstable angina. J Cardiol. 2013;62:77–81.
Murakami M, Iwasaki K, Kusachi S, Hina K, Hirota M, Hirohata S, Kamikawa S, Sangawa M, Yamamoto K, Shiratori Y. Nicorandil reduces the incidence of minor cardiac marker elevation after coronary stenting. Int J Cardiol. 2006;107:48–53.
Yang J, Zhang J, Cui W, Liu F, Xie R, Yang X, Gu G, Zheng H, Lu J, Yang X. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention. Anatol J Cardiol. 2015;15:125–31.
Iida S, Kinoshita H, Holford NHG. Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure. Br J Clin Pharmacol. 2008;66:352.
Iwakura K, Ito H, Okamura A, Koyama Y, Date M, Higuchi Y, Inoue K, Kimura R, Nagai H, Imai M. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis. Circ J. 2009;73:925–31.
Ishii H, Ichimiya S, Kanashiro M, Amano T, Matsubara T, Murohara T. Effects of intravenous nicorandil before reperfusion for acute myocardial infarction in patients with stress hyperglycemia. Diabetes Care. 2006;29:202–6.
The IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the impact of Nicorandil in angina (IONA) randomised trial. Lancet. 2002;359:1269–75.
Horinaka S, A Y, Yagi H, Ishimitsu T, Yamazaki T, Suzuki S, Kohro T, Nagai R. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese coronary artery disease (JCAD) study. Circ J. 2010;74(3):503–9.
Akai K, Wang Y, Sato K, Sekiguchi N, Sugimura A, Kumagai T, Komaru T, Kanatsuka H, Shirato K. Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 1995;26:541–7.
Wang A, Chen F, Xie Y, Guo Z, Yu Y. Protective mechanism of nicorandil on rat myocardial ischemia-reperfusion. J Cardiovasc Med. 2012;13:511.
Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction. J Nucl Med. 2007;48:1676.
Krumenacker M, Roland E. Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy. J Cardiovasc Pharmacol. 1992;20(Suppl 3):S93.